Recent Updates
Recently added Catalysts

MK0686

Phase 2

Osteoarthritis | Small molecule | Musculoskeletal |Merck & Company, Inc.|Last Updated: Dec 24, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment150
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00296569A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)PHASE2 COMPLETED 150Sep 1, 2005May 1, 2006Dec 24, 2014 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Pain relief at the knee and hip over 4 weeks of treatment as assessed by the WOMAC Pain Subscale.
over 4 weeks of treatment
Secondary Endpoints
Safety and tolerability over a 4-week treatment period
over a 4-week treatment period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0686DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — 65 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patients with a clinical and radiographic diagnosis of osteoarthritis of the hip or knee,either prior NSAID or Acetaminophen users within the ARA functional class I,II or III and with no clinically significant diseases * Patients required to demonstrate a flare of the signs an...

Unlock Eligibility Criteria